Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 1/20 | 0.48 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.45 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.45 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.45 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.45 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.45 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.45 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.45 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.45 |
| ▸ | CSNK1D | P48730 | 4/20 | 0.43 |
| ▸ | IDH1 | O75874 | 6/20 | 0.43 |
| ▸ | ACP1 | P24666 | 1/20 | 0.43 |
| ▸ | SUV39H1 | O43463 | 1/20 | 0.42 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.42 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2245455 | 0.94 | DYRK1A (0.49) | DYRK1ADGAT1HDAC3HDAC4HDAC1 | |
| SCHEMBL8358743 | 0.92 | DYRK1A (0.49) | DYRK1ADGAT1HDAC3HDAC4HDAC1 | |
| Hydrochloric Acid SCHEMBL29603030 | 0.91 | DYRK1A (0.48) | DYRK1ADGAT1HDAC3HDAC4HDAC1 | |
| Hydrochloric Acid SCHEMBL2247753 | 0.91 | DYRK1A (0.48) | DYRK1ADGAT1HDAC3HDAC4HDAC1 | |
| SCHEMBL2245948 | 0.90 | DYRK1A (0.49) | DYRK1ADGAT1HDAC3HDAC4HDAC1 | |
| SCHEMBL29603333 | 0.90 | DYRK1A (0.52) | DYRK1ADGAT1HDAC3HDAC4HDAC1 | |
| SCHEMBL2246217 | 0.90 | DYRK1A (0.52) | DYRK1ADGAT1HDAC3HDAC4HDAC1 | |
| SCHEMBL2245622 | 0.88 | DYRK1A (0.56) | DYRK1ADGAT1HDAC3HDAC4HDAC1 | |
| SCHEMBL2243455 | 0.87 | DYRK1A (0.50) | DYRK1ADGAT1HDAC3HDAC4HDAC1 | |
| SCHEMBL21066953 | 0.87 | DYRK1A (0.48) | DYRK1ADGAT1HDAC3HDAC4HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230093476-A1 | SUBSTITUTED FUSED IMIDAZOLE DERIVATIVES AND METHODS OF TREATING REFRACTIVE OCULAR DISORDERS | VTV THERAPEUTICS LLC | 2023-03-23 | — | — | US | disclosed |
| US-20210338644-A1 | Substituted Fused Imidazole Derivatives and Methods of Treating Sickle Cell Disease and Related Complications | VTV THERAPEUTICS LLC | 2021-11-04 | — | — | US | disclosed |
| US-20210283111-A1 | Methods of Inhibiting Osteoclastogenesis and Osteoclast Activity | VTV THERAPEUTICS LLC | 2021-09-16 | — | — | US | disclosed |
| US-20210069159-A1 | Bach1 Inhibitors in Combination with Nrf2 Activators and Pharmaceutical Compositions Thereof | VTV THERAPEUTICS LLC | 2021-03-11 | — | — | US | disclosed |
| US-10898475-B2 | Bach1 inhibitors in combination with Nrf2 activators and pharmaceutical compositions thereof | VTV THERAPEUTICS LLC (US) | 2021-01-26 | — | — | US | disclosed |
| US-10463652-B2 | Bach1 inhibitors in combination with Nrf2 activators and pharmaceutical compositions thereof | VTV THERAPEUTICS LLC (US) | 2019-11-05 | — | — | US | disclosed |
| US-20190076410-A1 | Bach1 Inhibitors in Combination with Nrf2 Activators and Pharmaceutical Compositions Thereof | VTV THERAPEUTICS LLC | 2019-03-14 | — | — | US | disclosed |
| US-10172840-B2 | Bach1 inhibitors in combination with Nrf2 activators and pharmaceutical compositions thereof | VTV THERAPEUTICS LLC (US) | 2019-01-08 | — | — | US | disclosed |
| US-20170231967-A1 | Bach1 Inhibitors in Combination with Nrf2 Activators and Pharmaceutical Compositions Thereof | VTV THERAPEUTICS LLC | 2017-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10463652-B2 | Bach1 inhibitors in combination with Nrf2 activators and pharmaceutical compositions thereof | BACH1, KEAP1, NFE2L2 | DYRK1A 3015/4885DGAT1 1909/4885HDAC3 1757/4885 |
| US-20210338644-A1 | Substituted Fused Imidazole Derivatives and Methods of Treating Sickle Cell Disease and Related Complications | HBB, HBG1, HBG2 | DYRK1A 4256/4885DGAT1 4713/4885HDAC3 1428/4885 |
| US-20190076410-A1 | Bach1 Inhibitors in Combination with Nrf2 Activators and Pharmaceutical Compositions Thereof | BACH1, KEAP1, NFE2L2 | DYRK1A 3015/4885DGAT1 1909/4885HDAC3 1757/4885 |
| US-20170231967-A1 | Bach1 Inhibitors in Combination with Nrf2 Activators and Pharmaceutical Compositions Thereof | BACH1, KEAP1, NFE2L2 | DYRK1A 3015/4885DGAT1 1909/4885HDAC3 1757/4885 |
| US-10898475-B2 | Bach1 inhibitors in combination with Nrf2 activators and pharmaceutical compositions thereof | BACH1, KEAP1, NFE2L2 | DYRK1A 3704/4885DGAT1 616/4885HDAC3 1000/4885 |
| US-20230093476-A1 | SUBSTITUTED FUSED IMIDAZOLE DERIVATIVES AND METHODS OF TREATING REFRACTIVE OCULAR DISORDERS | ALDH1A2, UACA, PDE6D | DYRK1A 2501/4885DGAT1 4749/4885HDAC3 231/4885 |
| US-20210283111-A1 | Methods of Inhibiting Osteoclastogenesis and Osteoclast Activity | NFATC1, CTSF, CTSB | DYRK1A 4322/4885DGAT1 3028/4885HDAC3 96/4885 |
| US-20210069159-A1 | Bach1 Inhibitors in Combination with Nrf2 Activators and Pharmaceutical Compositions Thereof | BACH1, KEAP1, NFE2L2 | DYRK1A 2930/4885DGAT1 1506/4885HDAC3 1191/4885 |
| US-10172840-B2 | Bach1 inhibitors in combination with Nrf2 activators and pharmaceutical compositions thereof | BACH1, KEAP1, NFE2L2 | DYRK1A 3015/4885DGAT1 1909/4885HDAC3 1757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.